摘要
用我所研制的必解癌Ⅱ号（ＢＪＡ－Ⅱ）在高转移人卵巢癌裸鼠皮下移植瘤模型上进行抗肿瘤治疗（ＢＪＡ－Ⅱ组），并与顺铂治疗（顺铂组）、ＢＪＡ－Ⅱ和顺铂治疗（联合用药组）及空白对照组（对照组）比较。治疗于裸鼠接种移植瘤的次日开始，将ＢＪＡ－Ⅱ按每天每只裸鼠１６ｍｇ的剂量混入饲料内经口投入，治疗５３天，每只裸鼠服药总量达８４８ｍｇ。结果：ＢＪＡ－Ⅱ抑制肿瘤生长，抑瘤率６３．７％，有２只裸鼠移植瘤消失。实验结束，ＢＪＡ－Ⅱ组平均瘤重与对照组比较，差异有显著意义（Ｐ＜０．０５）；ＢＪＡ－Ⅱ有抗肿瘤转移作用（ＢＪＡ－Ⅱ组中１只转移，对照组中４只转移）。ＢＪＡ－Ⅱ组治疗后周围血白细胞数量、自然杀伤细胞活性、脾重／体重比值、淋巴结窦性组织细胞增生等指标均优于顺铂组。表明：ＢＪＡ－Ⅱ在裸鼠体内具有抑制肿瘤生长和抗肿瘤转移、提高宿主免疫功能的作用。
ude mice with highly metastatic human ovariancarcinoma were treated with BJA-Ⅱ. This new agentwas made in our institute. Twenty-four experimentalmice were divided into 4 groups with 6 mice each. Themice, according to the treatment given them, were de-signated as: the BJA-Ⅱ group, the cisplatin group, thegroup with combination therapy and the controlgroup. Treatment began on the 2nd day after tumortransplantation. For BJA-Ⅱ, a dose of 16 mg permouse per day was administered orally. The total doseeach mouse received by the 53rd day was 848mg.The tumor growth inhibition rate was found to be63.7% in the BJA-Ⅱ group, the transplanted tumorsdisappeared in 2 mice. No significant difference in av-erage tumor weight was found between the BJA-Ⅱgroup and the control group (P<0.05). The antime-tastatic effect of BJA-Ⅱ (1 mouse with metastasis)was higher than that of the control group (4 mice withmetastasis). The influences on the immunofunction ofthe host were observed: the increase of the peripheralWBC count, the increase of NK cell activity, the in-crease in the ratio of spleen weight to body weight,and the histocyte increase in the lymph node sinuses,etc. All of these findings were better demonstrated inthe BJA-Ⅱ group than in the cisplatin group. The re-sults indicate that BJA-Ⅱ is provided with theeffectiveness of inhibiting tumor growth, is anti-metastastic and is capable of increasing theimmunofunction of the host.
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
1994年第7期404-407,共4页
Chinese Journal of Obstetrics and Gynecology
关键词
卵巢肿瘤
抗癌药
必解癌Ⅱ号
Antineoplasm agent Ovarianneoplasms Animal, laboratory Mice, nude
